1.
Wellington S, Hung DT. The Expanding Diversity of Mycobacterium tuberculosis Drug Targets. ACS Infect Dis. 2018;4(5):696-714. doi:10.1021/acsinfecdis.7b00255.
1.
Carey AF, Rock JM, Krieger IV, et al. TnSeq of Mycobacterium tuberculosis clinical isolates reveals strain-specific antibiotic liabilities. PLoS Pathog. 2018;14(3):e1006939. doi:10.1371/journal.ppat.1006939.
1.
Stanley SA, Grant SS, Kawate T, et al. Identification of novel inhibitors of M. tuberculosis growth using whole cell based high-throughput screening. ACS Chem Biol. 2012;7(8):1377-84. doi:10.1021/cb300151m.
1.
McMahon TC, Stanley S, Kazyanskaya E, Hung D, Wood JL. The first synthesis of an epidiselenodiketopiperazine. Org Lett. 2012;14(17):4534-6. doi:10.1021/ol3020094.
1.
Grant SS, Kawate T, Nag PP, et al. Identification of novel inhibitors of nonreplicating Mycobacterium tuberculosis using a carbon starvation model. ACS Chem Biol. 2013;8(10):2224-34. doi:10.1021/cb4004817.
1.
Kawate T, Iwase N, Shimizu M, et al. Synthesis and structure-activity relationships of phenyl-substituted coumarins with anti-tubercular activity that target FadD32. Bioorg Med Chem Lett. 2013;23(22):6052-9. doi:10.1016/j.bmcl.2013.09.035.
1.
Stanley SA, Barczak AK, Silvis MR, et al. Identification of host-targeted small molecules that restrict intracellular Mycobacterium tuberculosis growth. PLoS Pathog. 2014;10(2):e1003946. doi:10.1371/journal.ppat.1003946.
1.
Rock JM, Lang UF, Chase MR, et al. DNA replication fidelity in Mycobacterium tuberculosis is mediated by an ancestral prokaryotic proofreader. Nat Genet. 2015;47(6):677-81. doi:10.1038/ng.3269.
1.
Cohen KA, Abeel T, McGuire AM, et al. Evolution of Extensively Drug-Resistant Tuberculosis over Four Decades: Whole Genome Sequencing and Dating Analysis of Mycobacterium tuberculosis Isolates from KwaZulu-Natal. PLoS Med. 2015;12(9):e1001880. doi:10.1371/journal.pmed.1001880.